Relmada Therapeutics annual gross margin
2012
2013
Relmada Therapeutics Gross Margin Growth & History (RLMD)
Relmada Therapeutics's gross margin was 21.31% for fiscal 2013.
View full Relmada Therapeutics company overviewRelmada Therapeutics annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2013 | 2013-08-31 | 21.31% | −5.66 pp |
| 2012 · Aug 31 | 2012-08-31 | 26.97% | — |
Relmada Therapeutics quarterly gross margin
Q2.12
Q3.12
Q1.13
Q1.13
Q2.13
Q1.14
Q2.14
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2014 · Feb 28 | 2014-02-28 | −0.44% | −14.35 pp |
| Q1 2014 · Nov 30 | 2013-11-30 | 8.86% | −18.14 pp |
| Q2 2013 | 2013-05-31 | 49.21% | +24.04 pp |
| Q1 2013 · Feb 28 | 2013-02-28 | 20.55% | — |
| Q1 2013 · Nov 30 | 2012-11-30 | 13.91% | — |
| Q3 2012 | 2012-05-31 | 27.00% | — |
| Q2 2012 | 2012-02-29 | 25.17% | — |
Relmada Therapeutics gross margin trends
Across the available reported history, Relmada Therapeutics's gross margin decreased from 26.97% to 21.31%, a change of −5.66 percentage points. The latest reported quarter, Q2 2014 · Feb 28, shows −0.44%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Relmada Therapeutics filings at SEC.gov ↗